Bharat Biotech introduces world's first clinically proven conjugate Typhoid vaccine
The vaccine 'Typbar-TCV' offers long term protection and can be given to children as young as six months.
Hyderabad, August 26, 2013: Bharat Biotech launches the world's first clinically proven conjugate Typhoid vaccine 'Typbar-TCV' which offers long term protection and can be given to children of as young as six months. The vaccine is expected to be available in the market in the next couple of weeks and it will also be exported to countries in South East Asia, South America, Africa, Central Asia and South Asia.
It may be noted here that the company invested close to Rs 65 crore to develop this vaccine and it plans to get close to Rs 100 crore in business from its typhoid portfolio in the next couple of years from Rs 50 crore now.
While the price of the vaccines is yet to be announced, it is expected that it will be costlier than the company’s existing typhoid vaccine Typbar, which is priced at Rs 180 a dose.
According to World Health Organisation, typhoid causes 2.5 lakh to 6 lakh deaths each year.